StockData
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc. (VRCA) stock

VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$2.74−0.14 (-5.03%)

Close on Nov 20, 2026Market cap $47.07MP/E –Yield –

Verrica Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Verrica Pharmaceuticals's gross profit for the twelve months ending Mar 31, 2025 was $4.58M. For fiscal 2024 it was $4.97M, up 7.4% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2024Dec 31, 2024$4.97M+7.4%
FY2023Dec 31, 2023$4.62M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2025Mar 31, 2025$2.74M-12.4%
Q4 FY2024Dec 31, 2024-$456.00K-125.5%
Q3 FY2024Sep 30, 2024-$2.18M-183.3%
Q2 FY2024Jun 30, 2024$4.48M–
Q1 FY2024Mar 31, 2024$3.13M–
Q4 FY2023Dec 31, 2023$1.79M–
Q3 FY2023Sep 30, 2023$2.62M–

More Verrica Pharmaceuticals figures

See a number that looks wrong?